Ionis earns $40M on Spinraza advance; Five Prime axes Inhibrx deal

⇨ Ionis is picking up another big check from Biogen related to the rollout of Spinraza. The biotech $IONS garnered $40 million on approval of the price in Japan, bringing its total take to $435 million.

⇨ Five Prime Therapeutics is punting its $452 million research pact — which came with a $10 million upfront — with Inhibrx. The biotech axed the deal two days ago, according to an SEC filing.

⇨ Suzhou, China-based CF PharmTech raised $65 million in a D round to support its development and manufacturing work on new inhalation drugs. SDIC Fund Management Corporation led the round.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->